- By Wayne Rodrigo
- (General Dispatch) – Pfizer applied to the Indian government for regulatory authority regarding export prices to start production of covid-19 vaccines in India.
- Following the withdrawal of the application last month, the company is seeking consent again this time.
- The conflicts of interest that set back Pfizer’s first attempt were due to the drug regulations implemented in India. In the face of the blockade of raw material exports.
- For its part, India tried to give a greater projection to the vaccine manufactured by some Indian companies, such as the AstraZeneca vaccine.
- Once the clinical trials and other processes related to the vaccine are completed, the U.S. companies are anxious to begin work in India.
- The main fear of the U.S. companies is that regulations will be established to control the price.
- However, specialists assure that if these agreements were to be established, the Indian economy would receive a stimulus to accelerate its economic growth.
- The challenge for Pfizer is a titanic task, because it would be looking for an opportunity in a market generally controlled by China, on the Asian continent.
Adittional Information:
Breitbart: Report: Pfizer May Challenge China in Asian Market by Manufacturing Vaccine in India
The Times Of India: Pfizer wants to make vaccine in India if faster clearance, export freedom assured: Report
